Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Nancy Lin, MD (left) and Erica Mayer, MD, MPH
Because we recognize that metastatic breast cancer is not just a single disease, we personalize clinical trials to each patient's type of cancer and diagnosis, matching patients with the trial that is the most compelling and relevant for their kind of
breast cancer. We are conducting multiple clinical trials to study the effect of new targeted drugs, particularly in patients with metastatic disease. Much of the research work performed at Dana-Farber has resulted in treatment breakthroughs and new
standards of care for patients with metastatic disease.
See our full list of
clinical trials for metastatic breast cancer.
Participating in a clinical trial is a very personal decision, and a choice that is completely yours to make. If it feels right to you, there are several good reasons to participate:
Learn more about
clinical trials and whether participating in a clinical trial is right for you.
Presentation on several new therapies for HER2-positive metastatic breast cancer including kinase inhibitors, antibody drug conjugates, and immunotherapies, as well as patient-friendly resources for exploring clinical trials. View the presentation or view on SlideShare.
Presentation on several new clinical trials for triple negative metastatic breast cancer including antibody drug conjugates, and immunotherapy combinations, as well as patient-friendly resources for exploring clinical trials. View the presentation or view on SlideShare.
Ending Metastatic Breast Cancer for Everyone (EMBRACE) is a research study conducted at Dana-Farber Cancer Institute. This study began recruiting patients in 2009, with the aim of learning more about the biology of advanced breast cancer, as well as the
treatment experiences of patients living with it.
Each patient's progress is tracked by a study coordinator, and the information collected is used to help doctors understand more about the long-term journey of the metastatic breast cancer patients in this group. Investigators hope the study will bring
them closer to finding a cure for this disease.
The study also sponsors a metastatic breast cancer forum every year, as well as webcasts of topics relevant to patients with metastatic disease.
For more information on EMBRACE, please email
Research is particularly vital when it comes to cancer that has spread beyond the breast (metastatic). One hallmark of the
Susan F. Smith Center for Women's Cancers is the integration of research and patient care, and the equal investment in both. At a basic level, scientists seek to understand the basic
biology of how and why breast cancer can spread, and at a clinical level, clinician/scientists test potential therapies in patients. More than 30 clinical trials are now underway for women with metastatic breast cancer.
Harold J. Burstein, MD, PhD, provides an overview of the latest research in metastatic breast cancer presented at the San Antonio Breast Cancer Symposium in December 2019.
Research conducted through the
Specialized Program of Research Excellence (SPORE) led by
Eric Winer, MD, encompasses several metastatic breast cancer projects. This prestigious five-year grant funded by the National Cancer Institute includes projects aimed at identifying drug "targets" on breast
Here are some examples of our current metastatic breast cancer research advances.
New Patient Appointments
View highlighted recordings from the EMBRACE Metastatic Breast Cancer Forum Series, a series of online educational programs for patients, families, and loved ones.View forum recordings
At the Leading Edge of Breast Cancer Research: Metastatic Breast CancerLeaders of Dana-Farber’s Susan F. Smith Center for Women’s Cancers share updates on their groundbreaking work in metastatic breast cancer and how this work is providing new treatments for breast cancer patients.